The clinical research community came together in early February in Florica to explore all aspects of clinical trial innovation. With a focus on enabling collaboration, innovation, and strategic decision-making, the summit brought together more than 4,000 attendees, from 1,200 organizations, from 30 countries.
The 17th annual summit was held from February 3-6 in Rosen Shingle Creek, Orlando, Florida. Several PharmaLex experts attended the summit to gather insights, share their experience, and connect with colleagues in the industry. Team members share their feedback from the conference.
More than 300 companies had booths in the busy exhibit hall, which was buzzing with providers focused on patient centricity. Topics widely discussed included patient recruitment, the voice of the patient, healthcare access, and patient monitoring.
A key focus among the many attendees was digital innovation, and, in particular, artificial intelligence (AI). While some attendees indicated some skepticism about AI, the overall trend in clinical innovation seems to be a willingness to embrace AI for specific purposes. One area where there was a focus at the summit was generative AI to support clinical study writing and protocol writing.
Presentation feedback
Many of the presentations placed an emphasis on the need for flexibility when addressing issues and being able to make changes on the fly.
Another theme that recurred in several presentations was the reputational cost of delays. While much is said about the financial importance of getting a drug to the market quickly, clinical leaders say reputation is also crucial. That raised questions and considerations around how to rescue a trial that is failing, and the resources needed to do so.
One interesting topic that a speaker from a large pharmaceutical company raised during a discussion was how data from the trial master file (TMF) might be leveraged, analyzed, and then looped back into the design of the study to improve patient centricity. While companies often don’t consider the critical importance of the TMF, this type of thinking indicates a growing awareness of the TMF as an information asset.
SCOPE is recognized as one of the leading opportunities for the clinical community to connect, share insights and experiences, and learn about new developments.
We would like to hear from others who attended the summit. What were the main takeaways for you? What surprised you? And what do you consider to be the biggest trends or hype? Contact us at https://www.pharmalex.com/contact-us/
Next year’s SCOPE Summit will be held in the same location, from February 2-5.
